Tag

Takeda Pharmaceuticals Archives - Carey Danis & Lowe

Second Actos Bladder Cancer Lawsuit Goes to Trial in Baltimore

By | Actos, Pharmaceutical litigation, Uncategorized

actos_bladder_cancer_lawsuits_settlements_diabetes_litigation_fda_warningThe second Actos bladder cancer lawsuit is currently on trial in the Circuirt Court for the City of Baltimore.

The plaintiffs in the case, the family of Diep An, a former Actos user who died from bladder cancer in January 2012, filed their Actos lawsuit contending that the diabetes drug was the cause of Diep An’s bladder cancer and death.

In opening arguments delivered in early September, the plaintiffs’ legal counsel argued that Takeda Pharmaceuticals, the Japanese company responsible for the development and marketing of Actos, did not make patients aware about the risks involved with using Actos, specifically about the bladder cancer risk. According to the plaintiffs’ lawyer, Takeda Pharmaceuticals instead focused on Actos sales.

As detailed in a Bloomberg report, the Diep An Actos bladder cancer lawsuit is the second case in over 3,000 to go to trial. Of the 3,000 Actos lawsuits in the U.S., approximately 1,200 have been consolidated into a federal court in Louisiana, with the  first case set to go to trial in January 2014. Carey Danis & Lowe Actos lawyers are interested to see, come January, how the federal trial affects lawsuits across the nation.

Still on the market in the United States, but banned in both France and Germany following a French epidemiological study, Actos is a drug used to treat diabetes. Due to increased reports of patients developing bladder cancer while using Actos, the U.S. Food and Drug Administration (FDA), reviewed a ten year Actos study, whose results are due out next year.

In its review of the partial data from the collaborative study conducted by Takeda Pharmaceuticals and Kaiser Permanente Northern California, the FDA found that in patients taking high dosages of Actos for longer durations, there exists a higher risk of developing bladder cancer.

Plaintiffs have filed Actos bladder cancer lawsuits alleging that Takeda Pharmaceuticals knew about the bladder cancer risk, yet made the decision to dismiss it as the drug was released onto the market.

If you or someone you love has been harmed by Actos, the experienced lawyers and medical experts at Carey Danis & Lowe are here to help. Receive a free legal consultation about your Actos case, and get medical advice from one of our nurses.

Contact Carey Danis & Lowe today by calling 800.721.2519, or by submitting a personal injury claim form.

Carey Danis & Lowe Actos Cancer Lawyers Optimistic Following Cooper v. Takeda $6.5 Million Compensatory Award

By | Actos, Pharmaceutical litigation, Uncategorized

actos_bladder_cancer_lawsuits_settlements_diabetes_litigation_fda_warningA California jury recently awarded a compensatory package of $6.5 million to a plaintiff in an Actos bladder cancer lawsuit. The case, Cooper v. Takeda, was heard over a two month period in a California Superior Court.

The jury arrived at their decision agreeing with Cooper’s claim that Takeda Pharmaceuticals, the manufacturer of the diabetes drug Actos, did not supply adequate safety information about the association between Actos and bladder cancer.

The plaintiff in the case, Jack Cooper, was presented with a $5 million compensatory award. The jury also bestowed a $1.5 million compensatory award upon Cooper’s spouse. Takeda did not have to pay punitive damages in the Actos case.

Carey Danis & Lowe Actos cancer lawyers believe that the jury’s ruling in Cooper’s Actos case delivers much optimism to individuals who have been injured by Actos, and have subsequently filed lawsuits against Takeda.

With the first case having been settled, Takeda faces more than 3,000 Actos lawsuits, according to a Thomson Reuters report. Cooper v. Takeda Pharmaceuticals America Inc. was heard in a California Superior Court in Los Angeles, case number CGC-12-518535.

Actos cancer lawyers at Carey Danis & Lowe are currently offering free legal evaluations of Actos cases. If you or someone you love has been injured by Actos, contact a Carey Danis & Lowe Actos cancer lawyer today by phone at 800.721.2519 or by submitting a legal claim form.

Actos Bladder Cancer Lawsuit News: Pharmacologist Points to Takeda’s Fixation on Profits Over Consumer Safety

By | Actos, Pharmaceutical litigation, Uncategorized

Actos Bladder Cancer Lawsuit News: Pharmacologist Points to Takeda's Fixation on Profits Over Consumer SafetyThe first trial in more than 3,000 Actos lawsuits filed in the U.S. is currently being heard in a Los Angeles court. Lawyers at Carey Danis & Lowe reported last week that the first Actos trial began with revelatory information about Takeda Pharmaceutical’s misleading marketing strategy.

Apparently, the Japanese pharmaceutical company was knowledgeable of the health problems associated with Actos ingestion, but decided to hide that information in order to market the diabetes drug.

Since Carey Danis & Lowe’s update last week, the trial involving plaintiff, Jack Cooper, has convened again for opening arguments from both sides, and expert testimony from a pharmacologist.

Jack Cooper filed a lawsuit against the manufacturer of Actos, Takeda Pharmaceuticals, citing that the pharmaceutical company failed to warn Actos users and healthcare providers about the risks of using the diabetes medicine, especially about the link between Actos and bladder cancer.

A Bloomberg article about the trial states that Cooper developed bladder cancer in 2011. Though Cooper alleges his bladder cancer is a result of ingesting Actos for four years, a lawyer representing Takeda pointed to the plaintiff’s lifestyle to explain his current health condition.

On March 4, Howard Greenberg, a clinical pharamacologist, delivered expert testimony about Takeda’s priorities regarding Actos. Greenberg noted that upon analyzing internal Takeda emails, it became clear that profits from Actos took precedence over consumer safety.

The content of these emails reveals that Takeda executives were concerned about the drug’s viability on the market if pharmaceutical regulators, like the U.S. Food and Drug Administration, ordered that the Actos drug label include information about bladder cancer. These emails go on to express that a bladder cancer warning would be a “worst-case scenario”, according to Bloomberg.

Cooper’s case is being heard in a California Superior Court in Los Angeles, and has been filed as Cooper v. Takeda Pharmaceuticals America Inc.

The worst-case scenario being poor drug sales resulting from a bladder cancer warning illustrates Takeda’s egregious disregard for consumer safety. Lawyers at Carey Danis & Lowe work diligently for our clients to hold pharmaceutical companies accountable for the harm their products cause consumers.

If you or someone you love has been injured by the use of Actos, and as a result, has developed bladder cancer, you and your loved one may be eligible to receive compensation.

For a free legal evaluation and for more information about filing an Actos bladder cancer lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe today by calling 800.721.2519 or by submitting a legal claim form.

First Actos Trial in California Uncovers Takeda’s Deceptive Actos Marketing Tactics

By | Actos, Pharmaceutical litigation, Uncategorized

First Actos Trial in California Uncovers Takeda's Deceptive Actos Marketing TacticsIn 2003, Takeda Pharmaceuticals Inc. expressed concerns about whether Actos users could develop cancer. These reservations on the part of the Japanese pharmaceutical company came to light in court documents filed in a California Superior Court in Los Angeles.

The internal documents reveal that Takeda Pharmaceuticals went so far as to survey doctors about whether a diabetes drug with a label warning about the risk of developing bladder cancer would prevent them from writing a prescription for the drug. After reviewing responses, Takeda Pharmaceuticals concluded that a bladder cancer warning on the Actos label would have a debilitating impact on Actos sales.

Undertaking such a measure is a clear illustration of Takeda Pharmaceuticals’ market-driven philosophy wherein profits far surpass consumer safety in matters of importance.

These internal Takeda documents were filed in the first Actos lawsuit to go to trial. The case is Cooper v. Takeda Pharmaceuticals America, Inc. According to a Bloomberg News report on the Actos trial, there are currently 3,000 Actos lawsuits pending across the country.

These Actos lawsuits including Takeda losing its Actos patent last year are certain to factor in to the company’s reliance on the diabetes drug to be a big moneymaker in 2013. In March 2011, Bloomberg recorded that Actos comprised 27 percent of Takeda’s revenue. Though, this high revenue trend will likely change as Actos has developed a tarnished reputation due to its link to bladder cancer.

In another revealing court filing, Takeda relayed special instructions to its U.S. sales representatives. Essentially, the internal document stated that if safety concerns are not raised, then do not reveal anything about the risk of bladder cancer, and instead, focus on selling the drug.

In response to these documents, a Takeda representative has stated that these documents have been taken out of context.

Lawyers at Carey Danis & Lowe have been paying close attention to the court proceedings in this first Actos lawsuit to go to trial. For those who have been injured by Actos, and especially Actos users who have developed Actos bladder cancer, Carey Danis & Lowe is currently accepting Actos claims, and offering free legal evaluations.

For more information about filing an Actos lawsuit, contact an experienced defective drug lawyer at Carey Danis & Lowe today by calling 800.721.2519 or by submitting a legal claim form

First Actos Trial is Cooper v. Takeda Pharmaceuticals America Inc.

By | Actos, Pharmaceutical litigation, Uncategorized

First Actos Trial is Cooper v. Takeda Pharmaceuticals America Inc.The first Actos lawsuit has gone to trial in a California Superior Court in Los Angeles, known as Cooper v. Takeda Pharmaceuticals America Inc. Cooper v. Takeda is being heard by Judge Kenneth Freeman in California. The plaintiff in the case claims that Takeda failed to warn that one of the risks connected to the diabetes drug is bladder cancer.

To date, there are over 3,000 Actos bladder cancer lawsuits that have been filed against Takeda across the United States in states like California, Illinois, and Louisiana.

In Louisiana, approximately 1,200 Actos lawsuits have been consolidated into a multi-district litigation (MDL). Actos MDL court documents show that the first Actos MDL trial is scheduled for November 2014.

In a report from Bloomberg News, a Takeda representative has publicly stated that the pharmaceutical company has acted appropriately in its response to reports of patients developing bladder cancer linked to Actos ingestion.

However, a U.S. Food and Drug Administration (FDA) analyses of a ten year study conducted by Takeda Pharmaceuticals and Kaiser Permanente Northern California illustrates “increased risk of bladder cancer among patients with the longest exposure to Actos”. Furthermore, the FDA also cited an increased risk of developing bladder cancer in those individuals who ingest high doses of Actos.

Lawyers at Carey Danis & Lowe encourage individuals who have been injured by Actos to contact the law firm for a free legal evaluation and to file an Actos lawsuit. Carey Danis & Lowe believes that it is important to protect consumers and hold negligent pharmaceutical companies, like Takeda, responsible for releasing a harmful drug onto the market.

Contact an experienced trial lawyer at Carey Danis & Lowe by calling 800.721.2519 or by filling out the Carey Danis & Lowe legal claims form.

Takeda Pharmaceuticals Releases New Diabetes Drug with Bladder Cancer Causing Pioglitazone

By | Actos, Pharmaceutical litigation, Uncategorized

takeda_pharmaceuticals_actos_bladder_cancer_new_diabetes_drug_combination_alogliptinThe manufacturer of the diabetes drug Actos, a drug that is tied up in mounting complaints and lawsuits citing the development of bladder cancer, has received U.S. Food and Drug Administration (FDA) approval for a new diabetes drug known generically as alogliptin. The FDA approved three new alogliptin combination drugs for the treatment of type 2 diabetes along with an adjusted diet and exercise regimen.

Takeda has announced that it will release the three drug combinations onto the market beginning in the summer of 2013.

Takeda Pharmaceuticals, a Japanese pharmaceutical company, lost their patent over Actos, known generically as pioglitazone, back in August 2012. With more competition entering into the diabetes drug market, especially with generic versions of Actos, Takeda Pharmaceuticals has introduced three combinations of alogliptin, one of which includes pioglitazone, which is present in Actos.

The alogliptin and pioglitazone drug combination is known as Oseni.

A major concern with the release of Oseni is that, though it will be marketed as a separate drug from Actos, it still contains the same active ingredient present in Actos, known as pioglitazone, a notorious ingredient that has been linked to the development of bladder cancer.

As of yet, however, the only warning given for Oseni is that of congestive heart failure, which is similar to the safety alert the FDA released in August 2007 about Actos and congestive heart failure.

Though it may not be immediately apparent that Oseni proves to be just as harmful as Actos, it is easy to make such a deduction following the mountain of complaints and lawsuits that have sprouted up across the country pertaining to the development of bladder cancer. In light of this, it is egregious that Takeda Pharmaceuticals would release onto the market yet another drug containing an ingredient suspected of causing bladder cancer.

One possible motivation for Takeda’s lack of sensitivity to the harm caused by Actos and pioglitazone is the pharmaceutical giant’s efforts to increase profits. According to a Wall Street Journal article published in early February, Takeda has taken a huge hit in the marketplace with their profits dropping 14 percent. Furthermore, a Bloomberg News report cites that Takeda is anticipating a significantly lower net income through early 2015.

Lawyers at Carey Danis & Lowe are currently evaluating Actos bladder cancer cases. We are also closely monitoring Actos lawsuits being filed around the country. If you or someone you love has been injured by Actos, you and your loved one may be eligible to receive compensation.

For a free legal evaluation about your Actos case, contact an experienced trial lawyer at Carey Danis & Lowe at 800.721.2519.

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in Louisiana

By | Actos, Pharmaceutical litigation, Uncategorized

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in LouisianaParties involved in the Actos multi-district litigation (MDL) in the U.S. District Court for the Western District of Louisiana met for a Status Conference on January 24, 2013. The MDL is known as in re: Actos (Pioglitazone Products Liability Litigation) MDL No. 11-md-2299, and is being presided over by U.S. District Judge Rebecca F. Doherty.

During the most recent Actos MDL Status Conference, the court reviewed recent Actos filings in federal and state courts as well as any new developments since the Actos MDL’s last Status Conference in December 2012. According to an Actos MDL court document, the parties also discussed the progress of the discovery phase. The next Status Conference is scheduled for February 21, 2013.

Plaintiffs whose cases have been consolidated into the Actos MDL have filed their lawsuits against the manufacturer of Actos claiming that the drug caused serious health complications, including bladder cancer.

In a study conducted by Takeda Pharmaceuticals in collaboration with Kaiser Permanente, data shows an increased risk in the development of bladder cancer in patients who have been using Actos for more than 1 year. At this time, the FDA is reviewing information from the Takeda and Kaiser Permanente ten year study. In Europe, healthcare officials have banned sales of Actos following data released from a French epidemiological study that showed a strong link between the ingestion of Actos and the development of bladder cancer.

In other Actos related news, the manufacturer of Actos has received approval to sell a new diabetes drug in the U.S. According to a Bloomberg News report, the Japanese manufacturer of Actos, Takeda Pharmaceuticals, just received approval from the U.S. Food and Drug Administration (FDA) for a new diabetes medication known generically as alogliptin. Takeda Pharmaceuticals intends to market alogliptin in the U.S. by the brand name of Nesina.

Over a five year period, the FDA rejected the new diabetes medication twice before finally granting it approval this month. Whether this new diabetes drug comes with the risk of developing bladder cancer is still uncertain.

Lawyers at Carey Danis & Lowe are currently evaluating Actos claims. If you or someone you love has taken Actos and has subsequently developed bladder cancer, you may be eligible to receive recompense for your pain, suffering, medical expenses, and lost wages.

For a free legal evaluation about your Actos claim and to learn more about filing an Actos bladder cancer lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe at 800.721.2519 today.

Actos MDL 2299 Update: Periodic Review Established and Next Status Conference Scheduled

By | Actos, Pharmaceutical litigation, Uncategorized

Actos MDL 2299 Update: Periodic Review Established and Next Status Conference ScheduledAn Actos Multi-District Litigation (MDL) has been consolidated in Louisiana as of December 2011. The Actos MDL is being heard by U.S. District Judge Doherty in the U.S. District Court for the Western District of Louisiana. The MDL has been named In Re: Actos (Pioglitazone) Products Liability Litigation MDL No. 2299.

The most recent news coming from the Actos MDL regards an administrative order outlining how the MDL will be conducted. The Case Management Order, delivered on January 2, 2013, details nothing of the MDL’s purpose, but rather outlines a periodic review process. The reason for making arrangements for a periodic review is to give attorneys involved in the MDL, on both sides, the opportunity and ability to share ideas, updates, and recommendations pertaining to the how the MDL is administered.

The next Status Conference for the Actos MDL 2299 will be January 24, 2013.

Actos is a drug manufactured by Takeda Pharmaceuticals, and is prescribed to patients with type 2 diabetes. The drug was approved for use in the U.S. by the  U.S. Food and Drug Administration (FDA) in July 1999.

According to a CBS News report from June 2011, the French Medicines Agency banned sales of Actos after reviewing data gathered in a French government funded epidemiological study demonstrated a strong link between the use of Actos and the development of bladder cancer. Soon after France banned Actos, German health officials followed suit in banning new prescriptions of the drug to diabetic patients.

In America, the FDA is continues to review the safety of Actos. Upon parsing through interim data from a 10 year study being funded by Takeda Pharmaceuticals in collaboration with Kaiser Permanente Northern California, the FDA issued an Actos safety update in August 2011 about the increased risk of developing Actos linked bladder cancer after using the drug for more than one year. Though the FDA recognizes the risks of using Actos, their safety review remains ongoing.

Signs of bladder cancer include painful urination, red colored urine, blood in urine, severe pain in the pelvic region, and frequent need to urinate. If you or a loved one is currently using Actos or has used Actos in the past to treat type 2 diabetes, and you or your loved one has experienced any of these signs of bladder cancer, it is imperative to meet with a healthcare provider immediately.

Experienced pharmaceutical product liability lawyers at Carey Danis & Lowe understand the importance of holding pharmaceutical companies like Takeda Pharmaceuticals accountable for releasing drugs onto the market whose side effects have not been fully researched. It was only after Actos was on the market, and only after reports began piling up relating to Actos bladder cancer risks, did Takeda Pharmaceuticals decide to conduct a 10 year study looking into the safety of Actos.

Lawyers at Carey Danis & Lowe seek to work closely with clients in shedding light on such negligence. For a free legal consultation about your Actos case, and for more information about filing an Actos lawsuit, contact a lawyer at Carey Danis & Lowe by calling 800.721.2519.

Clear Connection Between Actos and the Development of Bladder Cancer

By | Actos, Pharmaceutical litigation, Uncategorized

Clear Connection Between Actos and the Development of Bladder CancerActos is a drug developed by Takeda Pharmaceuticals, and is prescribed to patients with type 2 diabetes. The drug Actos has been closely linked with bladder cancer. Plaintiffs in Actos lawsuits, and in consumer reports filed with the U.S. Food and Drug Administration (FDA), have claimed to have suffered from bladder cancer after using Actos.

In information provided by the manufacturer, Takeda Pharmaceuticals, data from their 10 year study indicates that in individuals who did not use Actos, there were 7 cases in 10,000 of the development of bladder cancer. For those people who have taken Actos for no specified amount of time, researchers saw that there were 8 patients in 10,000 who developed bladder cancer.

For those individuals who had used Actos for more than 1 year, there was an incidence of 10 cases in 10,000 demonstrating the development of bladder cancer.

From this data released by Takeda Pharmceuticals, it can be deduced that there exists a strong connection between the ingestion of Actos and the development of bladder cancer. In fact, there is a 40% increased risk of developing bladder cancer from having taken Actos for more than 12 months.

Takeda is planning to publish results from their 10 year study sometime this year.

Although undertaking an extensive 10 year study will provide incredibly important safety information regarding Actos, conducting such a study after the drug has been introduced onto the market and has negatively harmed so many lives exhibits an after-the-fact and negligent side of the manufacturer. An in-depth look at the diabetes drug should have been undertaken before millions of people were exposed to a drug with such negative side effects, in particular the development of bladder cancer.

If you or your loved one has suffered from Actos bladder cancer, you and your loved one may be entitled to receive compensation for your emotional and physical suffering as well as your financial losses due to medical expenses.

For more information about filing an Actos lawsuit and to discuss your Actos case, contact an experienced pharmaceutical product liability lawyer at Carey Danis & Lowe today at 800.721.2519.

Actos Time Line: The Fraught History Behind Takeda Pharmaceutical’s Diabetes Drug

By | Actos, Pharmaceutical litigation, Uncategorized

Actos Time Line: The Fraught History Behind Takeda Pharmaceuticals' Diabetes DrugIt has now come to light that Takeda Pharmaceuticals knew about the cancer risks associated with the ingestion of Actos, a drug they developed to treat type 2 diabetes. However, despite these known Actos bladder cancer risks, Takeda Pharmaceuticals began marketing and selling the drug upon U.S. Food and Drug Administration (FDA) approval in 1999.

 

The following time line offers a detailed look into the fraught history of Actos, from its approval to the current day legal proceedings:

  • July 1999 – The FDA approved Actos for the treatment of type 2 diabetes.
  • 2002 – The risk of heart failure while taking Actos became apparent, and as a result, the FDA required the Actos label to be updated with information about heart failure risks.
  • 2007 – The FDA mandated that the Actos label be updated to include a black-box warning about the Actos heart failure risks.
  • September 17, 2010 – After reviewing data from a 10-year epidemiological study funded by Takeda Pharmaceuticals, the FDA made an announcement that it would begin an its own investigation into the safety of Actos, and in particular the bladder cancer risk.
  • June 2011 – France announced discontinued Actos prescriptions and sales as a result of data gathered in an Actos study conducted by the French Medicines Agency from 2006 to 2009, which revealed a strong link between Actos and the development of bladder cancer.
  • June 2011 – The FDA released a warning about the risks of bladder cancer and Actos. The FDA warning mentioned that when Actos is taken for more than 12 months, there is an increased risk of developing bladder cancer. The FDA demanded the Actos label be updated with information about the bladder cancer risks.
  • July 12, 2011 – Takeda Pharmaceuticals issued an Actos recall in France.
  • July 21, 2011 – The European Medicines Agency ruled to keep Actos on the drug market, but made a recommendation that healthcare providers closely monitor patients taking Actos for any signs of bladder cancer. The EMA also recommended that a thorough screening process be established when considering prescribing Actos to new patients.
  • August 4, 2011 – The FDA (approved new warning label information about) the risk of developing bladder cancer while taking Actos.
  • September 2011 – The first Actos class action lawsuit is filed in Louisiana.
  • December 2011 – Actos lawsuits are consolidated into a Multidistrict Litigation (MDL) in Louisiana.
  • March 2012 – A former Takeda Pharmaceuticals employee, Dr. Helen Ge, sued Takeda Pharmaceuticals claiming that the pharmaceutical company deliberately withheld information about the safety of Actos from the FDA.
  • December 2012 – Defective drug lawyers at Carey Danis & Lowe are currently accepting Actos claims.

If you or a loved one has suffered from Actos bladder cancer, you may be entitled to receive compensation for your suffering and losses. Our experienced defective drug lawyers will provide you with the expert legal counsel required to hold Takeda Pharmaceuticals responsible for marketing and selling the defective drug, Actos.

For a free legal consultation regarding your Actos claim, contact a lawyer at Carey Danis & Lowe at 800.721.2519.